Skip to main content

Advertisement

SpringerLink
Log in

Prevalence of Self-Reported Venous Thromboembolism and Cardiovascular Risk Factors in Patients with Ulcerative Colitis: The GETAID FOCUS Study

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

An Editorial to this article was published on 18 March 2022

Abstract

Background and Aims

Patients with inflammatory bowel disease have an increased risk of venous thromboembolism (VTE) and cardiovascular disease (CVD). The study aims to determine the prevalence of CVD and VTE risk factors in a large population of patients with ulcerative colitis (UC).

Methods

We conducted a cross-sectional study in 33 French and Belgium referral centers. A questionnaire was developed to explore self-reported risk factors for VTE and CVD, based on the latest international guidelines, in consecutive patients with UC.

Results

A total of 1071 patients with UC were included. There were 539 women (50.3%), and the median age of patients was 44 years [32; 57]. The median disease duration was 10 years [6; 17]. In the cohort, 36.5% of patients reported no cardiovascular risk factor (CVRF) and 72% had ≤ 1 CVRF. Regarding cardiovascular risk markers (CVRM) 36.9% of patients reported no CVRM and 78% had ≤ 1 CVRM. Of the 1071 patients, 91.3% of patients reported no VTE strong risk factor and 96% had ≤ 1 VTE moderate risk factor.

Conclusion

This is the first cohort specifically designed to assess both VTE and CVD risks in patients with UC. More than one third of patients with UC had no CVRF and around three quarters had ≤ 1 CVRF. In addition, more than nine out of ten patients had no VTE strong risk factor and ≤ 1 moderate risk factor. Physicians should be aware of these factors in their patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Data Availability

The data underlying this article are available in the article and in its online supplementary material.

References

  1. Roda G, Chien Ng S, Kotze PG et al. Crohn’s disease. Nat Rev Dis Primer 2020;6:22.

    Article  Google Scholar 

  2. Ungaro R, Mehandru S, Allen PB et al. Ulcerative colitis. Lancet 2017;389:1756–1770.

    Article  Google Scholar 

  3. Harbord M, Annese V, Vavricka SR et al. The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis 2016;10:239–254.

    Article  Google Scholar 

  4. Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet 2010;375:657–663.

    Article  Google Scholar 

  5. Bernstein CN, Blanchard JF, Houston DS, Wajda A. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost 2001;85:430–434.

    Article  CAS  Google Scholar 

  6. Yuhara H, Steinmaus C, Corley D et al. Meta-analysis: the risk of venous thromboembolism in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2013;37:953–962.

    Article  CAS  Google Scholar 

  7. Nguyen GC, Sam J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 2008;103:2272–2280.

    Article  Google Scholar 

  8. Nguyen GC, Bernstein CN, Bitton A et al. Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. Gastroenterology 2014;146:835-848.e6.

    Article  Google Scholar 

  9. Sinh P, Cross R. Cardiovascular risk assessment and impact of medications on cardiovascular disease in inflammatory bowel disease. Inflamm Bowel Dis 2021;27:1107–1115. https://doi.org/10.1093/ibd/izaa258.

    Article  PubMed  Google Scholar 

  10. Bunu D-M, Timofte C-E, Ciocoiu M et al. Cardiovascular manifestations of inflammatory bowel disease: pathogenesis, diagnosis, and preventive strategies. Gastroenterol Res Pract 2019;2019:3012509.

    Article  Google Scholar 

  11. Singh S, Singh H, Loftus EV, Pardi DS. Risk of cerebrovascular accidents and ischemic heart disease in patients with inflammatory bowel disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2014;12:382-393.e1.

    Article  Google Scholar 

  12. Dagli N, Poyrazoglu OK, Dagli AF et al. Is inflammatory bowel disease a risk factor for early atherosclerosis? Angiology 2010;61:198–204.

    Article  CAS  Google Scholar 

  13. Biondi RB, Salmazo PS, Bazan SGZ et al. Cardiovascular risk in individuals with inflammatory bowel disease. Clin Exp Gastroenterol 2020;13:107–113.

    Article  CAS  Google Scholar 

  14. Piazza G, Goldhaber SZ. Venous thromboembolism and atherothrombosis: an integrated approach. Circulation 2010;121:2146–2150.

    Article  Google Scholar 

  15. Sun H-H, Tian F. Inflammatory bowel disease and cardiovascular disease incidence and mortality: a meta-analysis. Eur J Prev Cardiol 2018;25:1623–1631.

    Article  Google Scholar 

  16. Dorn SD, Sandler RS. Inflammatory bowel disease is not a risk factor for cardiovascular disease mortality: results from a systematic review and meta-analysis. Am J Gastroenterol 2007;102:662–667.

    Article  Google Scholar 

  17. Duricova D, Pedersen N, Elkjaer M et al. Overall and cause-specific mortality in Crohn’s disease: a meta-analysis of population-based studies. Inflamm Bowel Dis 2010;16:347–353.

    Article  Google Scholar 

  18. Jess T, Gamborg M, Munkholm P, Sørensen TIA. Overall and cause-specific mortality in ulcerative colitis: meta-analysis of population-based inception cohort studies. Am J Gastroenterol 2007;102:609–617.

    Article  Google Scholar 

  19. Sandborn WJ, Su C, Sands BE et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2017;376:1723–1736.

    Article  CAS  Google Scholar 

  20. European Medicines Agency. Increased risk of blood clots in lungs and death with higher dose of Xeljanz (tofacitinib) for rheumatoid arthritis. Published online March 20, 2019.

  21. Giménez Poderós T, Gallardo Borge S, Vazquez-Ferreiro P. Risk of venous thromboembolism associated with tofacitinib and baricitinib: a systematic review and indirect meta-analysis. Pharmacotherapy 2020;40:1248–1264.

    Article  Google Scholar 

  22. European Medicines Agency. EMA confirms Xeljanz to be used with caution in patients at high risk of blood clots. European Medicines Agency. Accessed March 2021. https://www.ema.europa.eu/en/medicines/human/referrals/xeljanz.

  23. The U.S. Food and Drug Administration. Xeljanz, Xeljanz XR (tofacitinib): Drug Safety Communication: Initial Safety Trial Results Find Increased Risk of Serious Heart-related Problems and Cancer with Arthritis and Ulcerative Colitis Medicine. FDA. Accessed March 2021. https://www.fda.gov/safety/medical-product-safety-information/xeljanz-xeljanz-xr-tofacitinib-drug-safety-communication-initial-safety-trial-results-find-increased.

  24. Piepoli MF, Hoes AW, Agewall S et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts)developed with the special contribution of the european association for cardiovascular prevention and rehabilitation (EACPR). Eur Heart J 2016;37:2315–2381.

    Article  Google Scholar 

  25. Konstantinides SV, Meyer G, Becattini C et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2020;41:543–603.

    Article  Google Scholar 

  26. Emanuel G, Charlton J, Ashworth M et al. Cardiovascular risk assessment and treatment in chronic inflammatory disorders in primary care. Heart Br Card Soc 2016;102:1957–1962.

    CAS  Google Scholar 

  27. Aarestrup J, Jess T, Kobylecki CJ et al. Cardiovascular risk profile among patients with inflammatory bowel disease: a population-based study of more than 100 000 individuals. J Crohns Colitis 2019;13:319–323.

    Article  Google Scholar 

  28. Kirchgesner J, Beaugerie L, Carrat F et al. Increased risk of acute arterial events in young patients and severely active IBD: a nationwide French cohort study. Gut 2018;67:1261–1268.

    Article  Google Scholar 

  29. Kirchgesner J, Nyboe Andersen N, Carrat F et al. Risk of acute arterial events associated with treatment of inflammatory bowel diseases: nationwide French cohort study. Gut 2020;69:852–858.

    Article  CAS  Google Scholar 

  30. Gill GS, Fernandez SJ, Malhotra N et al. Major acute cardiovascular events in patients with inflammatory bowel disease. Coron Artery Dis 2021;32:73–77.

    Article  Google Scholar 

  31. Cheng K, Faye AS. Venous thromboembolism in inflammatory bowel disease. World J Gastroenterol 2020;26:1231–1241.

    Article  CAS  Google Scholar 

  32. McKie K, McLoughlin RJ, Hirsh MP et al. Risk factors for venous thromboembolism in children and young adults with inflammatory bowel disease. J Surg Res 2019;243:173–179.

    Article  Google Scholar 

  33. McCurdy JD, Kuenzig ME, Smith G et al. Risk of venous thromboembolism after hospital discharge in patients with inflammatory bowel disease: a population-based study. Inflamm Bowel Dis 2020;26:1761–1768.

    Article  Google Scholar 

  34. Andrade AR, Barros LL, Azevedo MFC et al. Risk of thrombosis and mortality in inflammatory bowel disease. Clin Transl Gastroenterol 2018;9:142.

    Article  Google Scholar 

  35. Pfizer. Pfizer Shares Co-Primary Endpoint Results from Post-Marketing Required Safety Study of XELJANZ® (tofacitinib) in Subjects with Rheumatoid Arthritis (RA) | Pfizer. Accessed March 2021. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-shares-co-primary-endpoint-results-post-marketing.

  36. Sandborn WJ, Panés J, Sands BE et al. Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme. Aliment Pharmacol Ther 2019;50:1068–1076.

    Article  CAS  Google Scholar 

  37. Olivera PA, Zuily S, Kotze PG, et al. International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease. In Press.

Download references

Acknowledgments

To the FOCUS study group collaborators, for their valuable help in this work: Benjamin Pariente, Laurent Beaugerie, Phillipe Seksik, Anne Bourrier, Arnaud Bourrreille, Ariadne Desjeux, Guillaume Savoye, Stéphanie Auzou, Guillaume Cadiot, Alban Benezech, Nicolas Mathieu, Georgia Malamut, Karine Amouriaux, Hédia Brixi, Marion Simon, Daniel Benitah, Philippe Ah-Soune, Mathurin Fumery, Gilles Boschetti, Claire Gay, Mathias Vidon, Ginette Fotsing, Benoit Coffin, Cyrielle Gilletta, Jean Marie Reimund and Marie Bonnet-Dodel.

Funding

This study was supported by Pfizer.

Author information

Authors and Affiliations

  1. Department of Gastroenterology, University Hospital of Marseille Nord, University of Aix-Marseille, Chemin des Bourrely, 13015, Marseille, France

    Lucas Guillo & Mélanie Serrero

  2. Department of Gastroenterology, Groupe Hospitalier Henri Mondor-Albert Chennevier, APHP, EC2M3-EA7375, University of Paris Est Créteil, Créteil, France

    Aurélien Amiot

  3. Department of Gastroenterology, Saint-Eloi Hospital, University Hospital of Montpellier, Montpellier, France

    Romain Altwegg

  4. Department of Gastroenterology, Saint-Etienne University Hospital, Saint-Étienne, France

    Xavier Roblin

  5. Department of Gastroenterology, AP-HP, Hôpital Saint-Joseph, Paris, France

    Calina Atanasiu

  6. Université Clermont Auvergne, 3iHP, CHU Clermont-Ferrand, Service d’Hépato-Gastroentérologie, Inserm U1071, M2iSH, USC-INRA 2018, Clermont-Ferrand, France

    Anthony Buisson

  7. Department of Gastroenterology, Institut des Maladies de L’Appareil Digestif (IMAD), CIC Inserm 1413, Nantes University Hospital, Nantes, France

    Catherine Le Berre

  8. Department of Gastroenterology, University Hospital of Liège, Liège, Belgium

    Catherine Reenaers

  9. Assistance Publique – Hôpitaux de Paris, Hôpital Saint Louis, Université de Paris, Paris, France

    Jean-Marc Gornet

  10. CHU de Bordeaux, Hôpital Haut-Lévêque, Service d’Hépato-gastroentérologie et oncologie digestive – Université de Bordeaux, 33000, Bordeaux, France

    David Laharie

  11. Department of Gastroenterology, Paris Descartes University, Sorbonne Paris Cité, Cochin Hospital, APHP, Paris, France

    Vered Abitbol

  12. Department of Gastroenterology, Reims University Hospital, Reims, France

    Amélie Biron

  13. Department of Gastroenterology, Hautepierre Strasbourg University Hospital and INSERM U1113 IRFAC, University of Strasbourg, Strasbourg, France

    Bénédicte Caron

  14. Department of Gastroenterology and Inserm U1111-CIRI, Lyon-Sud University Hospital, Hospices Civils de Lyon, Pierre Bénite, France

    Stéphane Nancey

  15. Department of Gastroenterology, Hôpital de Bicêtre, Assistance Publique-Hôpitaux de Paris and Université Paris Saclay, Le Kremlin-Bicêtre, France

    Antoine Chupin

  16. Department of Gastroenterology, Institut Mutualiste Montsouris, Paris, France

    Antoine Blain

  17. Department of Gastroenterology, Besancon University Hospital, Besançon, France

    Lucine Vuitton

  18. Department of Gastroenterology, University Hospital of Nimes, Nîmes, France

    Ludovic Caillo

  19. Department of Gastroenterology, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, AP-HP, Hôpital Saint-Antoine, Sorbonne Université, Paris, France

    Julien Kirchgesner

  20. Univ, Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, 59000, Lille, France

    Maria Nachury

  21. Department of Gastroenterology, Inserm NGERE U1256, University Hospital of Nancy, University of Lorraine, Vandoeuvre-lès-Nancy, France

    Laurent Peyrin-Biroulet

Authors
  1. Lucas Guillo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aurélien Amiot
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mélanie Serrero
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Romain Altwegg
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xavier Roblin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Calina Atanasiu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Anthony Buisson
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Catherine Le Berre
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Catherine Reenaers
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jean-Marc Gornet
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. David Laharie
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Vered Abitbol
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Amélie Biron
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Bénédicte Caron
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Stéphane Nancey
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Antoine Chupin
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Antoine Blain
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Lucine Vuitton
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Ludovic Caillo
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Julien Kirchgesner
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Maria Nachury
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Laurent Peyrin-Biroulet
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

For the FOCUS Study Group

  • Benjamin Pariente
  • , Laurent Beaugerie
  • , Phillipe Seksik
  • , Anne Bourrier
  • , Arnaud Bourrreille
  • , Ariadne Desjeux
  • , Guillaume Savoye
  • , Stéphanie Auzou
  • , Guillaume Cadiot
  • , Alban Benezech
  • , Nicolas Mathieu
  • , Georgia Malamut
  • , Karine Amouriaux
  • , Hédia Brixi
  • , Marion Simon
  • , Daniel Benitah
  • , Philippe Ah-Soune
  • , Mathurin Fumery
  • , Gilles Boschetti
  • , Claire Gay
  • , Mathias Vidon
  • , Ginette Fotsing
  • , Benoit Coffin
  • , Cyrielle Gilletta
  • , Jean Marie Reimund
  •  & Marie Bonnet-Dodel

Contributions

LG wrote the article. MN, CR, LG and LPB conceived and supervised the study. LG performed the statistical analysis. LPB critically revised the manuscript. The manuscript was approved by all authors.

Corresponding author

Correspondence to Lucas Guillo.

Ethics declarations

Conflict of interest

L Guillo declares consulting fees for Abbvie. A Amiot declares counseling, boards, lecture, transports or fees from Abbvie, Hospira, Takeda, Gilead, Biocodex, Janssen, Ferring and MSD. M Serrero declares lecture and consulting fees for Abbvie, Celltrion, Ferring, Janssen, MSD, Takeda and Tillotts. R Altwegg declares counseling, boards, transports or fees from Abbvie, Amgen, Biogen, Ferring, Janssen, MSD, Pfizer, Takeda, Tillotts. A Buisson declares lecture and consulting fees for Abbvie, Amgen, Arena, Biogen, Janssen, MSD, Mayoly-Spindler, Norgine, Pfizer, Roche, Takeda and Tillots. C Le Berre has served as a consultant for Janssen and Gilead; reports receiving payment for lectures from AbbVie, Ferring Janssen, MSD, Pfizer and Takeda. C Reenaers has served as a speaker and advisory board member for Abbvie, Janssen, Pfizer, Takeda, Celltrion. JM Gornet has received personal fees from Amgen, Janssen Cilag, Sanofi,Takeda, Roche and Tillots Pharma. D Laharie declares counseling, boards, transports or fees from Abbvie, Biogaran, Biogen, BMS, Ferring, HAC-pharma, Janssen, Gilead, MSD, Novartis, Pfizer, Prometheus, Roche, Takeda, Theradiag, Tillots. V Abitbol declares counseling, boards, transports or fees from Janssen, Takeda, sandoz, Mylan, Amgen, Fresenius, Tillotts, Celltrion, Gilead, Pfizer. B Caron has received lecture and/or consulting fees from Abbvie, Amgen, Celltrion, Janssen, Takeda. S Nancey declares lecture and consulting fees for Abbvie, Celltrion, Amgen, Biogen, Janssen, Hospira/Pfizer, MSD, HAC, Fresenius, Takeda, Bristol Myers Squibb and Tillotts. L Vuitton has received lecture fees from Abbvie, MSD, Takeda, Ferring, Janssen and Pfizer, and research grants from MSD, Takeda and Pfizer. L Caillo declares lecture and consulting fees for Abbvie, Pfizer, Ferring, Janssen, Amgen, Biogen, Takeda and Tillotts. J Kirchgesner declares lecture and consulting fees from Roche, Pfizer, and Gilead. M Nachury declares lecture and consulting fees for Abbvie, Adacyte, Amgen, Arena, Biogen, CTMA, Ferring, Janssen, Mayoli-Spindler, MSD, Pfizer, Takeda. L Peyrin-Biroulet has served as a speaker, consultant and advisory board member for Merck, Abbvie, Janssen, Genentech, Mitsubishi, Ferring, Norgine, Tillotts, Vifor, Hospira/Pfizer, Celltrion, Takeda, Biogaran, Boerhinger-Ingelheim, Lilly, HAC- Pharma, Index Pharmaceuticals, Amgen, Sandoz, For- ward Pharma GmbH, Celgene, Biogen, Lycera, Samsung Bioepis, Theravance. The remaining authors have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

An editorial commenting on this article is available at https://doi.org/10.1007/s10620-022-07449-0.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 24 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Guillo, L., Amiot, A., Serrero, M. et al. Prevalence of Self-Reported Venous Thromboembolism and Cardiovascular Risk Factors in Patients with Ulcerative Colitis: The GETAID FOCUS Study. Dig Dis Sci 67, 4525–4532 (2022). https://doi.org/10.1007/s10620-022-07445-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-022-07445-4

Keywords

Search

Navigation